2 12 18
28
32
a
    59
    • a 3b
  • Faculty
    • 1f
  • Norbert Pardi
    • b
8
1a 2a

Faculty

61 16
19
1b
30

Norbert Pardi, PhD

78 faculty photo 48
Associate Professor of Microbiology
7 63
Department: Microbiology
4 1 23
1f Graduate Group Affiliations 8 a
b
1d
46 Contact information
 5b
476A Stemmler Hall
Philadelphia, PA 19104
26
2e Office: 215 746 6552
30
9f
Email: pnorbert@pennmedicine.upenn.edu
12
4 3 3 3 2 4 b 1f
13 Education:
21 8 MSc 26 (Biochemistry and Genetics) c
36 University of Szeged, Hungary, 2004.
 21 8 PhD 26 (Biochemistry and Genetics) c
36 University of Szeged, Hungary, 2011.
 c
3 27
Links
4f Lab Website
c
5 3 3 92 Permanent link
2 29
 
1d
25
21
b6 > Perelman School of Medicine   > Faculty   > Details a
1e 1d
76

Description of Research Expertise

21 mRNA therapeutics
e 29
23

Selected Publications

166 Weber Y, Böck D, Ivașcu A, Mathis N, Rothgangl T, Ioannidi EI, Blaudt AC, Tidecks L, Vadovics M, Muramatsu H, Reichmuth A, Marquart KF, Kissling L, Pardi N, Jinek M, Schwank G.: Enhancing prime editor activity by directed protein evolution in yeast. Nat Commun 15(1): 2092, Mar 2024.

 141 Ábrahám E, Bajusz C, Marton A, Borics A, Mdluli T, Pardi N*, Lipinszki Z.: Expression and purification of the receptor-binding domain of SARS-CoV-2 spike protein in mammalian cells for immunological assays. FEBS Open Bio 14(3): 380-389, Mar 2024.

 1f8 Fumagalli V, Ravà M, Marotta D, Di Lucia P, Bono EB, Giustini L, De Leo F, Casalgrandi M, Monteleone E, Mouro V, Malpighi C, Perucchini C, Grillo M, De Palma S, Donnici L, Marchese S, Conti M, Muramatsu H, Perlman S, Pardi N, Kuka M, De Francesco R, Bianchi ME, Guidotti LG, Iannacone M.: Antibody-independent protection against heterologous SARS-CoV-2 challenge conferred by prior infection or vaccination. Nat Immunol. Mar 2024.

 15d Wang HY, Li L, Nelson CS, Barfield R, Valencia S, Chan C, Muramatsu H, Lin PJC, Pardi N, An Z, Weissman D, Permar SR.: Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth. NPJ Vaccines 9(1): 38, Feb 2024.

 148 Matias J, Cui Y, Lynn GE, DePonte K, Mesquita E, Muramatsu H, Alameh MG, Dwivedi G, Tam YK, Pardi N, Weissman D, Fikrig E.: mRNA vaccination of rabbits alters the fecundity, but not the attachment, of adult Ixodes scapularis. Sci Rep 14(1): 496, Jan 2024.

 172 Kunkeaw N, Nguitragool W, Takashima E, Kangwanrangsan N, Muramatsu H, Tachibana M, Ishino T, Lin PJC, Tam YK, Pichyangkul S, Tsuboi T, Pardi N*, Sattabongkot J.: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax. NPJ Vaccines 8(1): 187, Dec 2023.

 1e3 Rizvi F, Lee YR, Diaz-Aragon R, Bawa PS, So J, Florentino RM, Wu S, Sarjoo A, Truong E, Smith AR, Wang F, Everton E, Ostrowska A, Jung K, Tam Y, Muramatsu H, Pardi N, Weissman D, Soto-Gutierrez A, Shin D, Gouon-Evans V.: VEGFA mRNA-LNP promotes biliary epithelial cell-to-hepatocyte conversion in acute and chronic liver diseases and reverses steatosis and fibrosis. Cell Stem Cell 30(12): 1640-1657, Dec 2023.

 159 Hogan MJ, Maheshwari N, Begg BE, Nicastri A, Hedgepeth EJ, Muramatsu H, Pardi N, Miller MA, Reilly SP, Brossay L, Lynch KW, Ternette N, Eisenlohr LC: Cryptic MHC-E epitope from influenza elicits a potent cytolytic T cell response. Nat Immunol. 11(24): 1933-1946, Nov 2023.

 128 Zhang L, More KR, Ojha A, Jackson CB, Quinlan BD, Li H, He W, Farzan M, Pardi N, Choe H.: Effect of mRNA-LNP components of two globally-marketed COVID-19 vaccines on efficacy and stability. NPJ Vaccines 1(8): 156, Oct 2023.

 ca Pine M, Arora G, Hart TM, Bettini E, Gaudette BT, Muramatsu H, Tombácz I, Kambayashi T, Tam YK, Brisson D, Allman D, Locci M, Weissman D, Fikrig E, Pardi N.* 2 a2 *corresponding author: Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Mol Ther 9(31): 2702-2714, Sep 2023.

 2c
7 1d
2c back to top
26 Last updated: 04/24/2024
34 The Trustees of the University of Pennsylvania c
1f
27
24
 
1d
18
1 49 2 2 1a 32 34
19
12 12 1a 14